Literature DB >> 12392822

Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection.

Abdelwahab Omri1, Zacharias E Suntres, Pang N Shek.   

Abstract

The bactericidal effectiveness of liposomal polymyxin B against Pseudomonas aeruginosa was investigated in an animal model of pulmonary infection. Polymyxin B was incorporated into liposomes composed of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and cholesterol (Chol) (2:1). Lung infection was induced in rats following intratracheal instillation of 10(7) colony-forming units (CFU) of P. aeruginosa (ATCC 27853) embedded in agar beads. Starting on day 3 post-infection, animals were treated daily, for 3 consecutive days, with saline, empty liposomes, free polymyxin B, or liposomal polymyxin B (2mg polymyxin B/kg body weight) by intratracheal instillation; animals were killed 24hr after the third drug instillation. Treatment of infected animals with liposomal polymyxin B significantly reduced the pulmonary bacterial counts (3.7+/-0.4log CFU/paired lungs) as compared with that of free polymyxin B (5.1+/-0.2log CFU/paired lungs). Treatment of infected animals with empty liposomes gave pulmonary bacterial counts similar to those obtained from the saline-treated group. Pulmonary infection with P. aeruginosa also resulted in lung injury as evidenced by increases in wet lung weight and decreases in angiotensin converting enzyme activity as well as increases in myeloperoxidase activity, an index of the inflammatory response. Treatment with free polymyxin B ameliorated the lung injuries induced by the microorganism, a protective effect that was more pronounced in the liposomal polymyxin B-treated group. The levels of polymyxin B in the lungs of the infected animals treated with the liposomal suspension were significantly higher (42.8+/-6.2 microg/paired lungs) compared with those treated with the free drug (8.2+/-0.4 microg/paired lungs). These data suggest that direct delivery of liposomal polymyxin B to the lung can be effective in the treatment of pulmonary infection with P. aeruginosa by enhancing retention of the antibiotic in the lung.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12392822     DOI: 10.1016/s0006-2952(02)01346-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  28 in total

1.  Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa.

Authors:  Clement Mugabe; Majed Halwani; Ali O Azghani; Robert M Lafrenie; Abdelwahab Omri
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

2.  Nanoparticles: Emerging carriers for drug delivery.

Authors:  Sagar R Mudshinge; Amol B Deore; Sachin Patil; Chetan M Bhalgat
Journal:  Saudi Pharm J       Date:  2011-04-21       Impact factor: 4.330

3.  The liposome of trehalose dimycolate extracted from M. bovis BCG induces antitumor immunity via the activation of dendritic cells and CD8+ T cells.

Authors:  Masanobu Shiga; Jun Miyazaki; Kozaburo Tanuma; Yoshiyuki Nagumo; Takayuki Yoshino; Shuya Kandori; Hiromitsu Negoro; Takahiro Kojima; Ryota Tanaka; Naoko Okiyama; Yasuhiro Fujisawa; Miyuki Watanabe; Sho Yamasaki; Hideyasu Kiyohara; Makoto Watanabe; Taka-Aki Sato; Hideaki Tahara; Hiroyuki Nishiyama; Ikuya Yano
Journal:  Cancer Immunol Immunother       Date:  2021-02-11       Impact factor: 6.968

4.  Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model.

Authors:  Jie He; Kamilia Abdelraouf; Kimberly R Ledesma; Diana S-L Chow; Vincent H Tam
Journal:  Int J Antimicrob Agents       Date:  2013-08-22       Impact factor: 5.283

5.  Interaction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulation.

Authors:  Stephanie J Wallace; Jian Li; Roger L Nation; Richard J Prankerd; Ben J Boyd
Journal:  J Pharm Sci       Date:  2012-05-23       Impact factor: 3.534

6.  Co-Delivery of Ciprofloxacin and Colistin in Liposomal Formulations with Enhanced In Vitro Antimicrobial Activities against Multidrug Resistant Pseudomonas aeruginosa.

Authors:  Shaoning Wang; Shihui Yu; Yuwei Lin; Peizhi Zou; Guihong Chai; Heidi H Yu; Hasini Wickremasinghe; Nivedita Shetty; Junhong Ling; Jian Li; Qi Tony Zhou
Journal:  Pharm Res       Date:  2018-08-09       Impact factor: 4.200

Review 7.  Nanotechnology-based drug delivery systems for control of microbial biofilms: a review.

Authors:  Matheus Aparecido Dos Santos Ramos; Patrícia Bento Da Silva; Larissa Spósito; Luciani Gaspar De Toledo; Bruna Vidal Bonifácio; Camila Fernanda Rodero; Karen Cristina Dos Santos; Marlus Chorilli; Taís Maria Bauab
Journal:  Int J Nanomedicine       Date:  2018-02-27

8.  Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection.

Authors:  Moayad Alhariri; Abdelwahab Omri
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

Review 9.  New antimicrobial strategies in cystic fibrosis.

Authors:  Mireille van Westreenen; Harm A W M Tiddens
Journal:  Paediatr Drugs       Date:  2010-12-01       Impact factor: 3.022

10.  Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis.

Authors:  Misagh Alipour; Zacharias E Suntres; Majed Halwani; Ali O Azghani; Abdelwahab Omri
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.